News Focus
News Focus
Followers 1
Posts 106
Boards Moderated 0
Alias Born 06/17/2016

Re: None

Thursday, 11/20/2025 2:33:11 PM

Thursday, November 20, 2025 2:33:11 PM

Post# of 516265
Dr Sabbagh came across as a kind and well informed Doctor. Just the type of person one would want representing Anavex as he mentioned 2x. His thoughts on EMA submission and acceptance, referenced the EMA's recent approval of the Mabs and the negative response they received because of this may be influencing their decisions now. However, he said they are still in the process despite negative opinion/decision. He also mentioned that he and Anavex have already spoken to the FDA regarding A2-73 in a very preliminary Type C meeting again (emphasizing very preliminary). He also mentioned that a big factor as to why not many USA trials are being done is cost. But specifically mentioned that if Anavex had to run P3 it would be done in the USA. This is my interpretation of what I heard in this presentation. Again Dr. Sabbagh came across as credible, relatable and highly skilled at what he does. Perfect for Anavex!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News